Clinical Trial Update: Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of the investigational agent E2609 in healthy subjects and an elderly coho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• E2609

Snippet

Sponsor: Eisai Inc. | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED